EMA: generally no product-specific GLs [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-09-20 09:52 (4666 d 00:03 ago) – Posting: # 11527
Views: 32,878

❝ If you succeed in convincing MHRA that spironolactone is a pro-drug, you would have to show BE only for one metabolite (active or not). I would opt for canrenone.


Good morning Helmut,

I'm not sure if I picked up some decaf by mistake this morning or I'm still hungover from a Thrusday night binge, but this bit above doesn't look quite right to me. According to the guideline:

Also for inactive prodrugs, demonstration of bioequivalence for parent compound is recommended. The active metabolite does not need to be measured.

So, if spironolactone can indeed be measured, I'm not sure it matters whether it's a prodrug or not. Did I miss something?:ponder:

Torn

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
224 visitors (0 registered, 224 guests [including 28 identified bots]).
Forum time: 09:56 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5